Table 1.

Univariate and multivariate competing-risks regression analysis of prognostic factors for very late relapse in the whole patient series, in ABVD treated patients and in ABVD treated patients with classical Hodgkin lymphoma.

	All patients (N = 1143, 66 events)				ABVDeq-treated patients (N = 1042, 50 events)				ABVDeq-treated patients with cHL (N = 978, 46 events)
	Univariate analysis		Multivariate analysisa		Univariate analysis		Multivariate analysisb		Univariate analysis		Multivariate analysisc
Variable	sHR (95% CI)	p valued	sHR (95% CI)	p valued	sHR (95% CI)	p value	sHR (95% CI)	p valued	sHR (95% CI)	p value	sHR (95% CI)	p valued
Age (≥45 vs. <45)	1.74 (1.04–2.90)	0.034	DNE		2.14 (1.20–3.81)	0.01	1.81 (0.93–3.51)	0.082	2.51 (1.39–4.53)	0.002	1.89 (0.95–3.74)	0.070
Gender (male vs. female)	1.43 (0.87–2.35)	0.155	DNE		1.44 (0.81–2.54)	0.211	DNE		1.81 (0.99–3.31)	0.053	DNE
Stage (IB/IIB/III/IV vs. IA/IIA)	1.49 (0.92–2.43)	0.107	DNE		1.30 (0.74–2.30)	0.364	DNE		1.15 (0.64–2.09)	0.634	DNE
B-symptoms (present vs. absent)	1.47 (0.90–2.41)	0.127	NE		1.35 (0.76–2.42)	0.306	NE		1.29 (0.70–2.36)	0.411	NE
Histology
(cHL vs. NLPHL)	0.67 (0.28–1.59)	0.359	NE		0.74 (0.25–2.14)	0.575	NE		NA		NA
(MC vs. all other)	2.47 (1.52–4.00)	<0.001	2.19 (1.28–3.73)	0.004	2.67 (1.54–4.65)	0.001	2.20 (1.17–4.14)	0.015	NA		NA
(MC vs. other cHL)	2.72 (1.64–4.52)	<0.001	NE		2.89 (1.63–5.15)	<0.001	NE		2.87 (1.61–5.12)	<0.001	2.21 (1.15–4.27)	0.018
(NLPHL vs. non-MC cHL)	2.21 (0.89–5.47)	0.087	NE		2.01 (0.67–6.05)	0.213	NE		NA		NA
Chemotherapy (MOPPeq vs. ABVDeq)	0.49 (0.27–0.91)	0.024	DNE		NA		NA		NA		NA
Radiotherapy (yes vs. no)	0.40 (0.24–0.64)	<0.001	0.35 (0.21–0.59)	<0.001	0.51 (0.29–0.89)	0.019	0.53 (0.28–1.03)	0.062	0.47 (0.26–0.84)	0.011	0.51 (0.26–1.01)	0.054
Anemia (present vs. absent)	1.11 (0.67–1.83)	0.686	NE		1.05 (0.59–1.86)	0.870	NE		0.93 (0.51–1.70)	0.811	NE
WBC (≥ 10 vs. <10 × 109/l)	0.69 (0.41–1.42)	0.147	NE		0.69 (0.39–1.24)	0.214	NE		0.55 (0.30–1.03)	0.061	DNE
Lymphopenia (present vs. absent)	0.47 (0.12–1.89)	0.285	NE		0.59 (0.14–2.41)	0.462	NE		0.64 (0.16–2.60)	0.529	NE
Albumin (<4 vs. ≥4 g/dl)	1.30 (0.73–2.30)	0.371	NE		1.19 (0.65–2.19)	0.574	NE		1.11 (0.58–2.11)	0.749	NE
ESR (≥50 vs. <50 mm/h)	0.55 (0.31–0.99)	0.047	0.46 (0.26–0.82)	0.008	0.53 (0.27–1.04)	0.067	0.49 (0.25–0.96)	0.039	0.54 (0.27–1.06)	0.071	0.50 (0.25–0.997)	0.049
IPS (≥3 vs. <3)	1.08 (0.57–2.04)	0.815	NE		1.23 (0.63–2.42)	0.544	NE		1.31 (0.66–2.59)	0.445	NE
VLR risk Score
(1 vs. 0)	4.31 (1.00–18.56)	0.050	NA		2.94 (0.67–13.00)	0.155	NA		2.68 (0.59–12.05)	0.200	NA
(2 vs. 0)	7.84 (1.82–33.67)	0.006	NA		6.56 (1.52–28.35)	0.012	NA		6.75 (1.56–29.23)	0.011	NA
(3–4 vs. 0)	15.35 (3.54–66.58)	<0.001	NA		11.47 (2.55–51.64)	0.001	NA		11.53 (2.56–52.00)	0.001	NA

sHR sub hazard ratio, 95% CI 95% confidence intervals, cHL classical Hodgkin lymphoma, DNE did not enter the model, NE not evaluated, NA not applicable, NS nodular sclerosis, MC mixed cellularity, NLPHL nodular lymphocyte-predominant Hodgkin lymphoma, MOPPeq MOPP or equivalent regimen, ABVDeq ABVD or equivalent regimen, ESR erythrocyte sedimentation rate, IPS International Prognostic Score, VLR very late relapses, VLR risk score no of risk 4 factors (MC histology, ESR < 50 mm/h, no RT, age ≥ 45 years).

Also evaluated in the model:

^aAge, gender, stage, treatment with ABVD or equivalents vs. MOPP or equivalents.

^bGender, stage.

^cGender, stage, leukocytosis.

^dFine and Gray model.